Clinical characteristics of recipients of highly purified peripheral blood stem cells
| Patient no. . | Age . | Date at first diagnosis . | Underlying disease before PBSCT and primary treatment . | Conditioning regimen . | Donor HLA-A, -B, -DRβ1 match . | CD34+ cell infusion × 106cells/kg . | CD3+ cells × 103 cells/kg . | Donor leukocyte infusion after PBSCT* . | Disease after PBSCT . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 7 | Innate | Innate T-cell defect, autoimmune hemolytic anemia† IV IG substitution | Busulfan 4 × 4 mg/kg | Mother; 3/6 antigens matched | 50 | 18.7 | No infusion | Chronic restrictive lung disease |
| Thiotepa 2 × 5 mg/kg | |||||||||
| Cyclophosphamide 4 × 50 mg/kg | |||||||||
| ALG 3 × 20 mg/kg | |||||||||
| 2 | 11 | 6 months before PBSCT | AML M4 CR2; del(11)(q23); initial hyperleukocytosis/CNS infiltration “*AML—BFM93” regimen | Busulfan 4 × 4 mg/kg Cyclophosphamide 2 × 60 mg/kg Melphalan 1 × 140 mg/m2 ATG 3 × 10 mg/kg | Unrelated; 6/6 antigens matched | 20.5 14.1‡ | 7 | Day +112 after PBSCT | Gut and skin GvHD1-153; autoimmune hemolytic anemia; CMV encephalitis |
| 3 | 9 | 5 months before PBSCT | AML M2 CR1; t(8;21); initial infiltration of CNS, orbitae, pleura, lymph nodes “AML—BFM93” regimen | Busulfan 4 × 4 mg/kg | Mother; 5/6 antigens matched | 13.4 | 13.6 | Days +72 and +100 after PBSCT | Autoimmune hemolytic anemia |
| Cyclophosphamide 2 × 60 mg/kg | |||||||||
| Thiotepa 2 × 5 mg/kg | |||||||||
| ATG 3 × 10 mg/kg | |||||||||
| OKT3 + methylprednisolone for graft-rejection prophylaxis |
| Patient no. . | Age . | Date at first diagnosis . | Underlying disease before PBSCT and primary treatment . | Conditioning regimen . | Donor HLA-A, -B, -DRβ1 match . | CD34+ cell infusion × 106cells/kg . | CD3+ cells × 103 cells/kg . | Donor leukocyte infusion after PBSCT* . | Disease after PBSCT . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 7 | Innate | Innate T-cell defect, autoimmune hemolytic anemia† IV IG substitution | Busulfan 4 × 4 mg/kg | Mother; 3/6 antigens matched | 50 | 18.7 | No infusion | Chronic restrictive lung disease |
| Thiotepa 2 × 5 mg/kg | |||||||||
| Cyclophosphamide 4 × 50 mg/kg | |||||||||
| ALG 3 × 20 mg/kg | |||||||||
| 2 | 11 | 6 months before PBSCT | AML M4 CR2; del(11)(q23); initial hyperleukocytosis/CNS infiltration “*AML—BFM93” regimen | Busulfan 4 × 4 mg/kg Cyclophosphamide 2 × 60 mg/kg Melphalan 1 × 140 mg/m2 ATG 3 × 10 mg/kg | Unrelated; 6/6 antigens matched | 20.5 14.1‡ | 7 | Day +112 after PBSCT | Gut and skin GvHD1-153; autoimmune hemolytic anemia; CMV encephalitis |
| 3 | 9 | 5 months before PBSCT | AML M2 CR1; t(8;21); initial infiltration of CNS, orbitae, pleura, lymph nodes “AML—BFM93” regimen | Busulfan 4 × 4 mg/kg | Mother; 5/6 antigens matched | 13.4 | 13.6 | Days +72 and +100 after PBSCT | Autoimmune hemolytic anemia |
| Cyclophosphamide 2 × 60 mg/kg | |||||||||
| Thiotepa 2 × 5 mg/kg | |||||||||
| ATG 3 × 10 mg/kg | |||||||||
| OKT3 + methylprednisolone for graft-rejection prophylaxis |
PBSCT indicates peripheral blood stem cell transplantation; IV, intravenous; IG, immunoglobulin; ALG, antilymphocyte globulin; AML, acute myeloblastic leukemia; CR2, second complete remission; CNS, central nervous system; ATG, antithymocyte globulin; GvHD, graft-versus-host disease; CMV, cytomegalovirus; CRI, first complete remission.
25 000 CD3+ cells/kg.
Patient underwent splenectomy.
On day +244, additional CD34+ cell infusion.
Oral prednisone therapy since day +120 after PBSCT.